180 related articles for article (PubMed ID: 22462038)
1. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
2. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
Endo I; Matsumoto T
Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
[TBL] [Abstract][Full Text] [Related]
3. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
Ono Y
J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
[TBL] [Abstract][Full Text] [Related]
5. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
Hagino H
Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol for the treatment of osteoporosis.
Noguchi Y; Kawate H; Nomura M; Takayanagi R
Clin Interv Aging; 2013; 8():1313-21. PubMed ID: 24101867
[TBL] [Abstract][Full Text] [Related]
7. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
8. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
[TBL] [Abstract][Full Text] [Related]
9. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
10. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function].
Takeuchi Y
Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
Takano T; Kondo S; Saito H; Matsumoto T;
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
[TBL] [Abstract][Full Text] [Related]
12. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis].
Hagino H
Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
Matsumoto T; Takano T; Saito H; Takahashi F
Bonekey Rep; 2014; 3():513. PubMed ID: 24818005
[TBL] [Abstract][Full Text] [Related]
14. [Eldecalcitol (ED-71)].
Endo I; Matsumoto T
Clin Calcium; 2011 Jan; 21(1):53-8. PubMed ID: 21187594
[TBL] [Abstract][Full Text] [Related]
15. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report.
Saito H; Kakihata H; Nishida Y; Yatomi S; Nihojima S; Kobayashi Y; Tabata H; Nomura M
J Bone Miner Metab; 2017 Jul; 35(4):456-463. PubMed ID: 27699492
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D3 analogs for the treatment of osteoporosis.
Hagino H
Can J Physiol Pharmacol; 2015 May; 93(5):327-32. PubMed ID: 25853632
[TBL] [Abstract][Full Text] [Related]
17. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
18. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
19. [Frontiers in vitamin D; basic research and clinical application. Inhibitory effects of eldecalcitol, an active vitamin D derivative, on bone resorption in vivo].
Harada S; Mizoguchi T; Takahashi N
Clin Calcium; 2011 Nov; 21(11):91-8. PubMed ID: 22040825
[TBL] [Abstract][Full Text] [Related]
20. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.
Hagino H; Takano T; Fukunaga M; Shiraki M; Nakamura T; Matsumoto T
J Bone Miner Metab; 2013 Mar; 31(2):183-9. PubMed ID: 23129180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
